John Butler

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

As a selected Showcase Company from the NCI SBIR Development Center's Investor Initiative, Tezcat Biosciences will be at #BIO2024 in San Diego June 3-6. Tezcat Biosciences is developing a receptor-independent drug delivery technology, initially positioned for RAS pathway activated cancers. We are seeking industry collaborations to expand our pipeline as our technology is payload and disease agnostic. If your company has an interesting, hard to deliver payload and/or works in the following disease areas, we would like to set up a time to meet at the event. #SmallMolecule #siRNA #Radiopharmaceutical #PROTAC #Immunomodulatory #EndosomeEscape #CardiovascularDisease #MASH #NASH #InflammatoryDisease #NeurodegenerativeDisease #InfectiousDisease #AnimalHealth To schedule a time to meet inside the event, please use BIO’s One-on-One Partnering™ System. Outside the event, please DM either Dr. Craig Ramirez, Ph.D. or Dr. Andrew D. Hauser to schedule a time to meet. #biotech #businessdevelopment #networking #partnering https://lnkd.in/eEDtKaAK

14

NAMI Oregon is proud to join Neurocrine Biosciences in supporting #TDAwarenessWeek, running from May 5-11. Tardive Dyskinesia (TD) is a condition characterized by persistent, involuntary movements affecting various parts of the body, such as the face, torso, limbs, and fingers or toes. These movements can vary from rapid and jerky to slow and writhing, significantly impacting those affected by TD. TD is often associated with prolonged use of antipsychotic medication, which may be necessary to treat mental illnesses like major depressive disorder and bipolar disorder. Approximately 600,000 Americans live with TD, and around 65% of them are undiagnosed. Let's raise awareness together and support those living with TD during #TDAwarenessWeek. Learn more at https://lnkd.in/g-atBE4x or www.TalkAboutTD.com.

1

Don’t miss this opportunity at the Gene Therapy Initiative 1st Annual Symposium on September 19, 2024 to engage our thriving San Diego community of researchers, life sciences, biotechnology and pharmaceutical companies in the gene therapy space. The Gene Therapy Initiative (GTI) Symposium will convene researchers and industry experts to share the latest scientific findings and facilitate new partnerships with the goal of expediting the delivery of stem cell and gene therapy treatments, especially for patients with rare genetic diseases. Program Highlights: *Exploratory talks on innovative gene modifying therapeutics and optimization of existing tools. *Updates on gene therapies that are the subject of academic research and commercial development. *Induced Pluripotent Stem-cell-based disease models to test gene therapies. *Interactive panel on resources and collaboration for developing therapies for rare diseases. *Opportunity to learn about 2024 GTI seed grant funded projects. *Poster session featuring faculty and student research. *Networking hour to foster connectivity amongst attendees. Please note, there is NO CME for this symposium.   For more information and to register, go to: https://lnkd.in/gJuEP_Kv #GeneTherapy #genetherapies #RNAtechnologies #ExVivoGeneTherapy #AAVgenetherapy #research #science #lifesciences #biotechnology #scientificmeeting

12

The Biopharmaceutical and Gene Therapy Terminology Guide A 600-plus term guide describing the use of spectroscopy and separation science for biopharma applications and also terms associated with biopharm technology. https://lnkd.in/gvHZGwq9

7

Are you attending #BIO2024? Our CBO Paul Wallace will be in San Diego June 3-6 and available to speak about how our unique technologies can enhance your biotherapeutics programs.    At Constructive Bio we recode entire genomes and engineer protein translation to enable the design of protein and peptide therapeutics that have unprecedented functionalities - creating the biomolecules of the future.     Together we can:   ✅ Develop the next-generation ADCs: optimize peptide and antibody drug conjugates (ADCs) by fine-tuning drug-antibody ratio (DAR) and payload location, incorporating dual payloads and improving the therapeutic index, stability and PK. (E. coli and CHO expression). ✅ Generate novel and stable incretin based therapies (GLP-1 RA and GIP etc) – and simplify their manufacture, and reduce COGs, by production in E. coli. ✅ Precisely locate multiple conjugation handles / click chemistries into therapeutics / modular proteins. ✅ Utilize a vast chemical space, beyond the 20 standard amino acids, significantly to improve the pharmaceutical properties and functionality of biological therapeutics.   Click here to set up a meeting https://lnkd.in/eAJSe8Zg or get in touch via email paul.wallace@constructivebio.com.

19

On May 23rd, join Upkara, AssayQuant Technologies Inc., and B2S Life Sciences for a webinar about lyophilization-free stabilization of biomolecules and kit reagents. https://hubs.li/Q02wxRXJ0 #assayreagents #formulationdevelopment #assaydevelopment #reagentstabilization #moleculardiagnostics #webinar #reagentstorage

3

Congrats to CpG Diagnostics’ founder Bodour Salhia, Ph.D & University of Southern California researchers for developing a blood test for early-stage ovarian cancer! CpG Diagnostics (2023 Cohort) is working to expand the liquid biopsy approach to ovarian cancer, a disease that is particularly difficult to diagnose. Early detection of cancer by liquid biopsy holds the potential to dramatically improve outcomes for patients by helping physicians diagnose and begin treatment earlier in the progression of the disease — perhaps even before patients exhibit symptoms. Join us in celebrating CpG Diagnostics, Founder & CEO Bodour Salhia, Ph.D, and the team for achieving this major milestone and their positive impacts in the realm of #cancerresearch! Read more about CpG Diagnostics in our April Newsletter: https://lnkd.in/gUznyX6T 📩 Sign up for our mailing list: https://lnkd.in/gtcdE6J2 #Sustainability #Innovation #Healthcare #CancerResearch #ClimateTech #LartaInstitute

14

2 Comments

AI used to create the first open source gene editor. A promising tool to foster the research in this field and accelerate #crisprtherapy development. #crispr #crisprcas9 #genetherapy #celltherapy #geneediting #genomeediting #rnatherapeutics #genometherapy https://lnkd.in/e2FkVChk

1

Welcome to CSUBIOTECH Created in 1987, the California State University (CSU) Biotechnology (CSUBIOTECH; https://lnkd.in/gddjG2BF) has the mission of providing vision, leadership and support for biotechnology education and research throughout the CSU to promote biotechnology and economic development in California. The strategic goals of CSUBIOTECH are to promote innovative biotechnology education and research across the CSU system and provide leadership in training California's biotechnology work force. This will enable CSU faculty to become better scholars and instructors, and for undergraduate, graduate and returning students to advance their careers and become leaders in the biotechnology sector in California and across the nation. It will also allow CSUBIOTECH to extend, develop and expand relationships with regional and industrial partners, and enhance general education across the CSU and California for better understanding of biotechnology issues, challenges, and opportunities. CSUBIOTECH provides grants and awards, organizes the annual CSU Biotechnology Symposium, promotes industry-responsive curricular innovations, and serves as a liaison between the CSU and government, regional and biotechnology industry partners, including philanthropic partners. Within CSU, CSUBIOTECH promotes biotechnology workforce development by supporting innovative coursework, real-world research experiences, and core resources for students and faculty across all 23 CSU campuses. The program is cross-cutting involving students, faculty and administrators from life sciences, physical sciences, health sciences, engineering, mathematics, agriculture, business and computer science departments and divisions, and more across the system, including the Chancellor’s Office. In 2008 CSUBIOTECH developed its first three-year strategic plan, approved by the CSU Chancellor to articulate the community’s purpose, values, and goals, while also framing annual operations. In March 2016 CSUBIOTECH was authorized to continue operations as a system-wide affinity group under Executive Order 1103. CSUBIOTECH is administered and managed by an Executive Director, based at SDSU, who reports to the CSU Chancellor through a 6-person Presidents’ Commission (drawn from Presidents of the 23 campuses). The Program Office at SDSU is staffed by an Administrative Support Coordinator, two Administrative Analysts, and a Student Program Assistant. The Program Office is advised and supported by an 18-member Strategic Planning Council comprising faculty and deans from some campuses and external representatives from industry, Govt and non-profit sector, and a 92-member-Faculty Consensus Group comprising of biotechnology faculty representatives and deans from all CSU campuses. Altogether, over 1,000 CSU students, faculty, deans, and administrators interact with the CSUBIOTECH program office yearly.

6

Biocom California recently invited Sapient to contribute an article for its Lifelines Magazine edition focused on innovations in #genetherapy and #celltherapy. https://lnkd.in/gC9YfQnM While cell- and gene-based treatments are advancing rapidly, spurred by a landmark year of FDA approvals, their development is not without challenges. We discuss how #multiomics for gene and cell therapy can deliver the novel insights needed to realize the incredible therapeutic potential represented in these pipelines today: https://lnkd.in/gC9YfQnM

21

🔬 Precision, Perfected. In the realm of scientific inquiry, every detail matters. That's why we're proud to introduce custom-labeled labware – because accuracy shouldn't be an afterthought. When a fellow scientist requested direct labeling on a glass NMR tube, we listened. Your experiments, your standards, meticulously met. Embrace the precision, streamline your workflow. Ready to elevate your lab experience? Let's discuss tailored solutions for your scientific pursuits. #NOSTICKERS #TubeLabeling #labefficiency #labautomation #LifeSciences

27

The CME Symposium on Mechanisms of Cellular Evolution is being organized by the Biology Integration Institute for Mechanisms of Cellular Evolution at Arizona State University. The event is scheduled to take place from November 6-9, 2024, in Tempe, AZ. The symposium is the third in a series of annual events focused on the emerging interdisciplinary field of evolutionary cell biology, ECB. This field combines evolutionary #biology and cell biology with other related disciplines, including biochemistry, biophysics, population genetics, molecular biology and mathematics. The symposium aims to bring together leading researchers and experts from diverse fields to discuss current advances and future directions in ECB, and to provide opportunities for interdisciplinary discussions, knowledge sharing and collaboration. #ASU #ASUBiodesign #ASUResearch

18

Dr. Nozomu Yachie, Deputy in our Pillar 4 (Functional Genomics & Structure-Function of VOCs) and The University of British Columbia led a team in developing a novel platform that provides many new ways of analyzing viral infection, cancer, and cell differentiation. His team’s new time-machine-like system called CloneSelect opens avenues for in-depth analysis of various biological phenomena across human, mammalian, yeast, and bacterial systems. The new system uses CRISPR-Cas9 genome editing. Cells are barcoded and propagated, then subjected to experiments. This innovative platform enables the isolation of target clones showing desired phenotypes or genotypes over time. Read more: https://ow.ly/FFmS50RwyVk

3

Come visit booth 133 in Anaheim next week to learn more about Evosphere Monodisperse HPLC columns. New C18/AR and C18/PFP stationary phases gives resolution enhancements to complex lipodomic and metabolomic analysis. #evosphere #HPLC #ASMS #Monodisperse #UHPLC

4